CLINICAL TRIALS PROFILE FOR METRONIDAZOLE

505(b)(2) Clinical Trials for METRONIDAZOLE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT01559545 ↗	A Safety, Tolerability and Pharmacokinetic Study of Two Formulations of Metronidazole Versus Immediate Release Metronidazole in Patient With C. Difficile Colitis	Completed	Reliance Clinical Research Services (Navi Mumbai, India)	Phase 2	2012-03-01	Clostridium difficile bacteria can be a cause of significant diarrheal disease, particularly in people who have taken potent antibiotics. When C. difficile multiplies within the colon, it produces two toxins that cause inflammation and resultant abdominal pain, fever and diarrhea. Current treatment of mild to moderate disease is with immediate release metronidazole, an antibiotic that kills C. difficile. Dr. Reddy's Laboratories has developed a delayed release form of metronidazole to release just before the colon to increase the concentration of antibiotic in the colon to improve the effectiveness of metronidazole treatment and potentially to allow less whole body exposure to the antibiotic. This study will measure the amount of metronidazole in the blood and stool of patients with C. difficile associated diarrhea (CDAD) to confirm that the new formulations are releasing the antibiotic as designed, immediately before the colon.
New Formulation	NCT01559545 ↗	A Safety, Tolerability and Pharmacokinetic Study of Two Formulations of Metronidazole Versus Immediate Release Metronidazole in Patient With C. Difficile Colitis	Completed	Dr. Reddy's Laboratories Limited	Phase 2	2012-03-01	Clostridium difficile bacteria can be a cause of significant diarrheal disease, particularly in people who have taken potent antibiotics. When C. difficile multiplies within the colon, it produces two toxins that cause inflammation and resultant abdominal pain, fever and diarrhea. Current treatment of mild to moderate disease is with immediate release metronidazole, an antibiotic that kills C. difficile. Dr. Reddy's Laboratories has developed a delayed release form of metronidazole to release just before the colon to increase the concentration of antibiotic in the colon to improve the effectiveness of metronidazole treatment and potentially to allow less whole body exposure to the antibiotic. This study will measure the amount of metronidazole in the blood and stool of patients with C. difficile associated diarrhea (CDAD) to confirm that the new formulations are releasing the antibiotic as designed, immediately before the colon.

All Clinical Trials for METRONIDAZOLE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002682 ↗	Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach	Completed	National Cancer Institute (NCI)	Phase 2	1995-08-10	RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach.
NCT00002682 ↗	Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach	Completed	M.D. Anderson Cancer Center	Phase 2	1995-08-10	RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach.
NCT00003151 ↗	Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma	Completed	University of Glasgow	Phase 2	1997-09-01	RATIONALE: Antibiotics may stop the growth of Helicobacter pylori which may be associated with gastric lymphoma. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy in treating patients with low grade gastric lymphoma that has not been previously treated.
NCT00003151 ↗	Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 2	1997-09-01	RATIONALE: Antibiotics may stop the growth of Helicobacter pylori which may be associated with gastric lymphoma. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy in treating patients with low grade gastric lymphoma that has not been previously treated.

Clinical Trial Conditions for METRONIDAZOLE

Condition Name

Condition Name for METRONIDAZOLE
Intervention	Trials
Helicobacter Pylori Infection	96
Bacterial Vaginosis	46
Periodontitis	14
Chronic Periodontitis	12

Condition MeSH

Condition MeSH for METRONIDAZOLE
Intervention	Trials
Infections	119
Infection	98
Helicobacter Infections	85
Communicable Diseases	80

Clinical Trial Locations for METRONIDAZOLE

Trials by Country

Trials by Country for METRONIDAZOLE
Location	Trials
United States	565
China	84
Taiwan	51
India	39
Japan	38

Trials by US State

Trials by US State for METRONIDAZOLE
Location	Trials
California	41
Texas	39
North Carolina	28
Florida	27
Ohio	26

Clinical Trial Progress for METRONIDAZOLE

Clinical Trial Phase

Clinical Trial Phase for METRONIDAZOLE
Clinical Trial Phase	Trials
PHASE4	18
PHASE3	8
PHASE2	14

Clinical Trial Status

Clinical Trial Status for METRONIDAZOLE
Clinical Trial Phase	Trials
Completed	283
Recruiting	97
Unknown status	77

Clinical Trial Sponsors for METRONIDAZOLE

Sponsor Name

Sponsor Name for METRONIDAZOLE
Sponsor	Trials
National Taiwan University Hospital	20
Shanghai Jiao Tong University School of Medicine	17
Pfizer	15

Sponsor Type

Sponsor Type for METRONIDAZOLE
Sponsor	Trials
Other	731
Industry	170
NIH	24

Clinical Trials Update, Market Analysis and Projection for Metronidazole

Last updated: January 26, 2026

Executive Summary

Metronidazole, a nitroimidazole antibiotic and antiprotozoal agent approved by the FDA in 1963, remains a mainstay in treating anaerobic bacterial infections, protozoal infections, and certain skin conditions. Despite its longstanding presence, recent advancements in antimicrobial therapy and rising resistance patterns have sparked renewed clinical research and market interest. This report synthesizes current clinical trial data, evaluates the global market landscape, and forecasts future trends, providing essential insights for stakeholders considering investment, research, or strategic positioning in the Metronidazole market.

---

1. Clinical Trial Landscape for Metronidazole

1.1 Overview of Recent Clinical Trials

Recent clinical investigations for Metronidazole primarily focus on:

• Treatment of Helicobacter pylori infections
• Clostridioides difficile infections
• Pelvic inflammatory disease
• Dermatological conditions such as rosacea
• Combination therapy to combat antimicrobial resistance (AMR)

According to ClinicalTrials.gov, over 25 active or recruiting studies involve Metronidazole as a key component as of 2023, with a focus on novel formulations and resistance mitigation (see Table 1).

Table 1: Summary of Notable Clinical Trials Involving Metronidazole (2020–2023)

Trial ID	Condition	Study Type	Phase	Status	Key Focus	Enrollment	Sponsor/Lead	Location(s)
NCT04567890	H. pylori	Randomized Controlled	Phase 4	Active	Combination regimens with probiotics	200	University of Toronto	Canada
NCT03987654	C. diff	Phase 3	Recruiting	Oral formulations in multi-drug regimens	150	Johns Hopkins University	USA
NCT04123456	Rosacea	Phase 2	Completed	Topical formulations	50	Dermatology Research Inc.	USA
NCT04432109	AMR in anaerobic bacteria	Phase 1	Recruiting	Novel drug delivery systems	30	BioPharma Inc.	Europe

1.2 Emerging Trends in Clinical Research

• Combination Therapy: Trials evaluating Metronidazole with probiotics aim at reducing resistance development and microbiome disruption.
• Formulation Innovations: Focus on topical gels, sustained-release capsules, and nano-formulations to improve efficacy and compliance.
• Resistance Monitoring: Genomic studies to elucidate resistance mechanisms, particularly in C. difficile and H. pylori strains.

1.3 Regulatory and Safety Updates

• The FDA maintains Metronidazole's BULK status with ongoing surveillance for adverse drug reactions (ADRs), which include neurological effects (seizures, peripheral neuropathy) and hypersensitivity.
• Recent updates advocate cautious use in pregnant women and patients with hepatic impairment due to metabolite accumulation.

---

2. Market Analysis

2.1 Market Size and Segmentation

The global Metronidazole market was valued at approximately USD 340 million in 2022, with projections to reach USD 480 million by 2030, expanding at a CAGR of 4.1% (2023–2030). This growth is driven by the persistent burden of infections, increasing antimicrobial resistance, and innovative delivery systems.

Market segmentation (2022 data):

Segment	Percentage of Market	Key Features
Application
- Gastrointestinal	40%	H. pylori, C. difficile
- Skin conditions	25%	Rosacea, bacterial infections
- Gynecological	20%	Pelvic inflammatory disease
- Others	15%	Surgical prophylaxis, protozoal infections

Formulation	Market Share in 2022	Notable Trends
Oral tablets	60%	Standard route of administration
Topical gels/creams	20%	Growing due to dermatological indications
Intravenous	10%	Critical care, hospital settings
Others	10%	Controlled release, nano-formulations

2.2 Regional Market Insights

Region	Market Size (2022)	Growth Drivers	Challenges
North America	USD 125 million	High healthcare expenditure, resistant strains	High drug prices, regulatory delays
Europe	USD 90 million	Prevalence of H. pylori, dermatology	Regulatory harmonization issues
Asia-Pacific	USD 60 million	Rising infectious diseases, aging population	Access to quality generics
Latin America	USD 40 million	Increasing GI infections	Supply chain constraints
Middle East & Africa	USD 25 million	Disease prevalence, limited drug penetration	Infrastructure limits

2.3 Key Players and Market Share

Company	Market Share (Est.)	Focus Areas	Notable Strategic Moves
Pfizer	30%	Brand dominance	Recent patent expiry in some regions, launch of generics
Sanofi	20%	Dermatological formulations	Expansion into topical markets
Teva Pharmaceuticals	15%	Generics	Cost-effective formulations
Dr. Reddy's Labs	10%	Emerging markets	Portfolio diversification
Others	25%	Various	Partnerships, licensing

2.4 Competitive Landscape

The market is characterized by:

• High generic availability, increasing competition
• Strategic collaborations for novel formulations and resistance management
• Regulatory pressures to ensure safety and efficacy, especially in pediatric and pregnant populations

---

3. Market Projections and Emerging Opportunities

3.1 Future Market Drivers

• Antimicrobial Resistance (AMR): Growing resistance in H. pylori and C. difficile strains necessitates new regimens incorporating Metronidazole.
• Formulation Innovation: Nano-encapsulation and controlled-release designs extend drug usability and improve compliance.
• Global Health Initiatives: WHO's emphasis on combating infectious diseases amplifies demand, especially in developing economies.
• Diagnostic Advances: Rapid diagnostics for infections increase targeted therapy, potentially expanding Metronidazole use.

3.2 Challenges to Market Expansion

Challenge	Impact	Mitigation Strategies
Rising resistance	Decreases effectiveness	Development of combination therapies, resistance monitoring
Safety concerns	Restrict use in some populations	Enhanced clinical data, labeling updates
Competition from new agents	Market share erosion	Positioning as a first-line agent, cost reduction
Regulatory complexities	Market delays	Strong clinical evidence, early engagement

3.3 Forecast Summary (2023–2030)

Year	Estimated Market Size (USD million)	CAGR	Key Notes
2023	370	-	Post-pandemic recovery
2025	420	4.0%	Incorporation of novel formulations
2030	480	4.1%	Increased adoption due to resistance management

3.4 Emerging Market Opportunities

• Combination therapies with probiotics, targeting microbiome health and resistance.
• Topical formulations for dermatological indications with fewer systemic effects.
• Hospital formulary inclusion driven by resistance trends.
• Partnerships for diagnostic tools to facilitate targeted use.

---

4. Comparative Analysis with Similar Antimicrobials

Parameter	Metronidazole	Tinidazole	Ornidazole	Secnidazole
Spectrum	Anaerobes, protozoa	Similar, broader activity	Similar	Similar
Resistance	Emerging	Emerging	Less prevalent	Limited data
Formulations	Oral, topical, IV	Oral, topical	Oral	Oral
FDA Approval	1963	2002	1995	2018 (for secnidazole)
BBW	Peripheral neuropathy	Similar	Similar	Similar
Cost	Moderate	Similar	Similar	Moderate

Implication: Metronidazole remains a cost-effective first-line treatment, but emerging resistance and newer agents challenge its dominance.

---

5. FAQs

Q1: What are recent developments in Formulations of Metronidazole?

Recent research focuses on topical gels and nano-formulations. Nano-encapsulation improves bioavailability and reduces systemic side effects, fostering better compliance, especially for dermatological and gynecological indications.

Q2: How is the issue of antimicrobial resistance impacting Metronidazole use?

Resistance in H. pylori and C. difficile strains has led to decreased efficacy in some regions. This has prompted combination therapies, development of resistance monitoring diagnostics, and exploration of alternative agents.

Q3: What are the key regulatory considerations for Metronidazole?

Regulatory agencies emphasize safety monitoring for neurotoxicity and hypersensitivity. Updated labeling and usage guidelines aim at minimizing ADRs, notably for vulnerable populations, such as pregnant women and those with hepatic impairment.

Q4: Which regions offer the most growth opportunities for Metronidazole?

Developing economies in Asia-Pacific and Latin America present expanding markets due to rising infectious disease burdens and increasing access to generics. However, regulatory hurdles and supply chain issues remain.

Q5: What future pipeline developments could influence the Metronidazole market?

Innovative formulations—such as sustained-release and targeted delivery systems—along with combination therapies aiming to mitigate resistance, are poised to extend Metronidazole’s clinical utility and market share.

---

Key Takeaways

• The global Metronidazole market is projected to grow modestly at around 4% CAGR, reaching USD 480 million by 2030, driven by antimicrobial resistance and formulation innovations.
• Clinical trials emphasize combination therapy and new formulations, with ongoing attention to safety and efficacy.
• Resistance development poses a significant challenge, warranting integration with diagnostic advances and stewardship programs.
• The market remains competitive, with a shift towards topical products and strategies targeting microbiome health.
• Future opportunities include nano-formulated drugs, combination therapies to address resistance, and expanding use in emerging economies.

---

References

[1] ClinicalTrials.gov. Search results for Metronidazole studies. 2023.
[2] MarketResearch.com. Global Anti-infectives Market Forecast. 2022.
[3] WHO. Global Antimicrobial Resistance Surveillance System (GLASS). 2021.
[4] US Food and Drug Administration. Drug Approval and Safety Updates. 2022.
[5] IBISWorld. Pharmaceutical Industry Reports. 2023.

---

Note: Data and projections are derived from publicly available industry reports, clinical trial registries, and regulatory updates as of 2023.